Cell Therapy Manufacturing Market to Reach $23.2 Billion by 2036, Growing at 14.1% CAGR
The global cell therapy manufacturing market is projected to grow from $6.2 billion in 2026 to $23.2 billion by 2036, expanding at a 14.1% CAGR, driven by the commercialization of advanced therapies.
The global market for cell therapy manufacturing is set for significant expansion over the next decade, with projections indicating a rise from USD 6.2 billion in 2026 to USD 23.2 billion by 2036. This growth represents a compound annual growth rate (CAGR) of 14.1%, according to analysis by Future Market Insights (FMI).
Key drivers for this expansion include an increasing number of approved cell-based therapies, growing commercial Good Manufacturing Practice (GMP) capacity, and the wider adoption of automated closed processing systems. The market is expected to generate an incremental opportunity of USD 17.0 billion within the forecast period.
Commercial scale manufacturing dominates the market segments, accounting for an estimated 58.0% of demand in 2026. Viral vector production leads in technology, holding a 32.0% share, reflecting its critical role in gene transfer for engineered cell therapies.
India is identified as the fastest-growing country market with a CAGR of 17.2%, followed by Japan at 16.4%. The report suggests that as cell therapy manufacturing becomes more complex, developers require robust batch identity and automated processing, positioning manufacturers with both scalable GMP operations and regulatory expertise for success.